ASH 2020 | CANOVA: venetoclax + dexamethasone for t(11;14) R/R myeloma
Shaji Kumar
• 11 Dec 2020
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the ongoing Phase III CANOVA trial (NCT03539744) where patients with translocation 11;14 (t(11;14)) positive relapsed/refractory (R/R) multiple myeloma have been randomized to receive either venetoclax or pomalidomide in combination with dexamethasone. Previous data has shown venetoclax and dexamethasone may provide benefits specifically to patients with t11;14. There is no data currently available on the CANOVA trial, however Dr Kumar hopes to demonstrate the efficacy and safety profile of the combination among this cohort. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
